Last reviewed · How we verify
Norvir
At a glance
| Generic name | Norvir |
|---|---|
| Also known as | Ritonavir |
| Sponsor | Saint Michael's Medical Center |
| Target | UDP-glucuronosyltransferase 1-1, Cytochrome P450 2C9, Multidrug and toxin extrusion protein 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- COVID-19
- Chronic hepatitis C
- Human immunodeficiency virus infection
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Paresthesia
- Oral paresthesia
- Rash
- Fatigue
- Asthenia
- Skin rash/allergy
Serious adverse events
- Dehydration
- Hypotension
- Syncope
- Renal insufficiency
- Acute ergot toxicity
- Vasospasm
- Ischemia of extremities
- Third-degree AV block
- Second-degree AV block
- First-degree AV block
Key clinical trials
- RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms (PHASE2)
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (PHASE1, PHASE2)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial (PHASE2)
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norvir CI brief — competitive landscape report
- Norvir updates RSS · CI watch RSS
- Saint Michael's Medical Center portfolio CI